One of the most common complications of treatment to reduce blood sugar levels is hypoglycemia, most frequently seen in patients being treated with insulin (i.e., all patients with type 1 diabetes as well as patients with type 2 diabetes on insulin), but also in patients with type 2 diabetes receiving insulin secretagogue (sulfonylurea and meglitinides) treatment. The gene discussed is INS; the disease is type 1 diabetes mellitus.